Use of Immune Profiling Panel to assess the immune response of septic patients for prediction of worsening as a composite endpoint.

Sepsis induces intense, dynamic and heterogeneous host response modulations. Despite improvement of patient management, the risk of mortality and healthcare-associated infections remains high. Treatments to counterbalance immune response are under evaluation, but effective biomarkers are still lacking to perform patient stratification.

A 9-mRNA signature measured from whole blood by a prototype PCR panel predicts 28-day mortality upon admission of critically ill COVID-19 patients.

Immune responses affiliated with COVID-19 severity have been characterized and associated with deleterious outcomes. These approaches were mainly based on research tools not usable in routine clinical practice at the bedside. We observed that a multiplex transcriptomic panel prototype termed Immune Profiling Panel (IPP) could capture the dysregulation of immune responses of ICU COVID-19 patients at admission.

Mortality Prediction in Sepsis With an Immune-Related Transcriptomics Signature: A Multi-Cohort Analysis.

Background: Novel biomarkers are needed to progress toward individualized patient care in sepsis. The immune profiling panel (IPP) prototype has been designed as a fully-automated multiplex tool measuring expression levels of 26 genes in sepsis patients to explore immune functions, determine sepsis endotypes and guide personalized clinical management. The performance of the IPP gene set to predict 30-day mortality has not been extensively characterized in heterogeneous cohorts of sepsis patients.

[Interventional methods in diagnostics of the breast -- a new vacuum biopsy system for the breast in routine clinical practice].

Aim: To evaluate the diagnostic potential of the new vacuum-assisted method VacuFlash (VF) in clinical routine of breast diagnostics.

Method: From april 2002 to march 2003, the new sonographically guided vacuum-assisted system VacuFlash was used in 75 patients with a BI-RADS 5 lesion (analogue). The patients were aged between 31-75 yrs (median: 51 yrs), the size of the lesions measured 8-33 mm (median: 14 mm).

Assessment of breast cancer tumor size depends on method, histopathology and tumor size itself*.

Purpose: Mammography (MG), breast (BU) and axillary ultrasound (AU), and clinical examination (CE) are commonly used for clinical staging. These different methods were compared in order to assess the accuracy of clinical tumor staging (cT).

Method: About 503 breast cancer (BC) patients were prospectively measured by MG, ultrasound and clinical examination.

[Phantom study for the detection of simulated lesions in five different digital and one conventional mammography system].

Purpose: Experimental phantom study for the detection of simulated lesions with five different digital and one conventional screen-film mammography system.

Materials And Methods: Three radiographs were obtained at various configurations of the phantom with one conventional screen-film system (Mammomat 3000 N) (Siemens), five digital systems (high resolution computed radiography system [Fuji/Siemens], one a-Si detector [GE Medical Systems], two a-Se detectors [Siemens; Hologic / Lorad] and one CCD detector [Fischer Imaging]), applying the same exposure parameters. The Wisconsin Mammographic Random Phantom, Model 152 A, was used.

[Experimental investigations at the new digital mammographic system].

Purpose: Experimental investigations of a new digital mammography system.

Materials And Methods: The digital mammography system SenoScan (Fischer Imaging) is based on 4 charged coupled devices (CCD) (slot detector). The pixel size is 50 micro m, field of view 21 x 29 cm (2), effective quantum efficiency (DQE) (0) 50 %, spatial resolution 10 lp/mm, and memory depth 12 bit.

Experimental investigations of image quality in X-ray mammography with a conventional screen film system (SFS) and a new full-field digital mammography unit (DR) with a-Se-detector.

Purpose: Determination of image quality of a new digital mammography system with an a-Se-detector.

Material And Method: Radiograms of the Wisconsin Mammographic Random Phantom, Modell 152 A (Radiation Measurements Inc., Wisconsin) were acquired using a conventional film screen and a digital system.